• Thu, November 11, 2021
Silvan Tuerkcan Maintained (TSHA) at Buy with Decreased Target to $38 on, Nov 11th, 2021
Silvan Tuerkcan of JMP Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $40 to $38 on, Nov 11th, 2021.
Silvan has made no other calls on TSHA in the last 4 months.
There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Silvan's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Silvan
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $39 on, Wednesday, August 18th, 2021
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $60 on, Tuesday, August 17th, 2021
- Gil Blum of "Needham" Initiated at Strong Buy and Held Target at $45 on, Friday, July 16th, 2021
Like: 👍
